Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25784969 | 0.81 | CREBBP (0.44) | GSK3BDRD2DRD3BRD4CREBBP | |
| SCHEMBL15529305 | 0.79 | DRD2 (0.34) | GSK3BDRD2DRD3IDH1GRIN1 | |
| SCHEMBL24317426 | 0.78 | DRD2 (0.35) | GSK3BDRD2DRD3IDH1GRIN1 | |
| SCHEMBL24316219 | 0.78 | DRD2 (0.35) | GSK3BDRD2DRD3IDH1GRIN1 | |
| SCHEMBL20282717 | 0.73 | GSK3B (0.45) | GSK3BDRD2DRD3CREBBPIDH1 | |
| SCHEMBL26639299 | 0.73 | DRD2 (0.37) | GSK3BDRD2DRD3IDH1GRIN1 | |
| Quinoline SCHEMBL28268598 | 0.72 | ALDH1A1 (0.47) | BRD4CREBBPIDH1ALDH1A1 | |
| SCHEMBL16823472 | 0.72 | IDH1 (0.37) | IDH1ALDH1A1 | |
| SCHEMBL8039039 | 0.71 | GSK3B (0.39) | GSK3BDRD2DRD3IDH1 | |
| SCHEMBL24640337 | 0.70 | SIGMAR1 (0.35) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | GSK3B 1327/4885DRD2 4565/4885DRD3 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.